Epirubicin and Docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: results from two successive phase II studies. Radiol Oncol. 2013;47(1). Accessed October 25, 2026. https://radioloncol.com/index.php/ro/article/view/728